Exposure & Response Prevention (EX/RP) for Obsessive-Compulsive Disorder

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Pennsylvania, Philadelphia, PA
Obsessive-Compulsive Disorder
Exposure & Response Prevention (EX/RP) - Behavioral
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

Studies show that hormones affect the brain's fear extinction network, which is relevant for therapy involving exposure and response prevention (EX/RP), a first-line treatment for obsessive compulsive disorder (OCD). This study will examine the effect of delivering EX/RP to women during different phases in their menstrual cycle to determine the effects of hormones on the fear extinction network and on their OCD symptoms.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Obsessive-Compulsive Disorder

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: Baseline to approximately 4 weeks later

Week 4
OCD Symptoms
fMRI
rs fMRI

Trial Safety

Safety Progress

1 of 3

Other trials for Obsessive-Compulsive Disorder

Trial Design

3 Treatment Groups

Active Comparator
1 of 3
Experimental 1
1 of 3
Experimental 2
1 of 3
Active Control
Experimental Treatment

120 Total Participants · 3 Treatment Groups

Primary Treatment: Exposure & Response Prevention (EX/RP) · No Placebo Group · N/A

Experimental 1
Behavioral
Experimental Group · 1 Intervention: Exposure & Response Prevention (EX/RP) · Intervention Types: Behavioral
Experimental 2
Behavioral
Experimental Group · 1 Intervention: Exposure & Response Prevention (EX/RP) · Intervention Types: Behavioral
Active Comparator
Behavioral
ActiveComparator Group · 1 Intervention: Exposure & Response Prevention (EX/RP) · Intervention Types: Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exposure & Response Prevention (EX/RP)
2014
N/A
~80

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to approximately 4 weeks later
Closest Location: University of Pennsylvania · Philadelphia, PA
Photo of Hospital of the University of Pennsylvania 1Photo of Hospital of the University of Pennsylvania 2Photo of University of Pennsylvania 3
2011First Recorded Clinical Trial
4 TrialsResearching Obsessive-Compulsive Disorder
1053 CompletedClinical Trials

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
1,797 Previous Clinical Trials
36,106,442 Total Patients Enrolled
1 Trials studying Obsessive-Compulsive Disorder
Research Foundation for Mental Hygiene, Inc.OTHER
55 Previous Clinical Trials
16,142 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,490 Previous Clinical Trials
1,765,951 Total Patients Enrolled
60 Trials studying Obsessive-Compulsive Disorder
12,967 Patients Enrolled for Obsessive-Compulsive Disorder
New York State Psychiatric InstituteOTHER
453 Previous Clinical Trials
135,888 Total Patients Enrolled
24 Trials studying Obsessive-Compulsive Disorder
912 Patients Enrolled for Obsessive-Compulsive Disorder
New York UniversityOTHER
198 Previous Clinical Trials
299,572 Total Patients Enrolled
Helen B Simpson, MD, PhDPrincipal InvestigatorNew York State Psychiatric Institute
1 Previous Clinical Trials
12 Total Patients Enrolled
1 Trials studying Obsessive-Compulsive Disorder
12 Patients Enrolled for Obsessive-Compulsive Disorder
Edna B Foa, PhDPrincipal InvestigatorUniversity of Pennsylvania

Eligibility Criteria

Age 18 - 65 · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are willing and able to give written informed consent after full explanation of study procedures.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.